Bicycle raises $61M in downsized IPO, joining fellow biotechs on Nasdaq who have hauled in $1.6B collectively
A splashy syndicate, some big name partnerships and a technology designed to deliver a therapeutic payload more precisely have enticed public investors to Bicycle Therapeutics’ Nasdaq debut, which totaled at $61 million.
The biotech priced its downsized IPO $BCYC — in which insiders purchased up to $25 million — at $14, the low end of the range, a month after penciling in $86 million in the S-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
